Tweaked ‘New Drugs’ Flouted Price Approval Norms In India
Pharmaceutical firms face more flak in India for allegedly flouting pricing norms – this time more than 200 formulations were allegedly launched in the country without seeking price approvals, though some companies claim they are fully compliant with the norms.
You may also be interested in...
India has clamped down on the country's burgeoning market for irrational fixed-dose combinations (FDCs), weeding out more than 300 such products – a move that is seen as denting the industry sharply but being welcomed by physicians given the lack of therapeutic rationale for most of these medicines and the growing challenge of drug resistance in the case of anti-infectives.
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.